©The Author(s) 2016.
World J Gastroenterol. Nov 14, 2016; 22(42): 9378-9386
Published online Nov 14, 2016. doi: 10.3748/wjg.v22.i42.9378
Published online Nov 14, 2016. doi: 10.3748/wjg.v22.i42.9378
Table 2 Observed toxicity according Common Terminology Criteria for Adverse Events v 4.03 (n = 52) n (%)
| CTCAE v 4.03 | ||
| All grades | Severe1 | |
| Hematological | ||
| Anemia | 28 (53.8) | 5 (9.6) |
| Neutropenia | 24 (46.2) | 17 (32.7) |
| Thrombocytopenia | 14 (26.9) | 3 (5.8) |
| Non Hematological | ||
| Diarrhea | 35 (67.3) | 13 (25.0) |
| Nausea and vomiting | 22 (42.3) | 5 (9.6) |
| Asthenia | 49 (94.2) | 5 (9.6) |
| Peripheral Neutropenia | 17 (32.7) | 4 (7.7) |
| Hepatic toxicity | 4 (7.7) | 1 (1.9) |
- Citation: Guion-Dusserre JF, Bertaut A, Ghiringhelli F, Vincent J, Quipourt V, Marilier S, Tharin Z, Bengrine-Lefevre L. Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy. World J Gastroenterol 2016; 22(42): 9378-9386
- URL: https://www.wjgnet.com/1007-9327/full/v22/i42/9378.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i42.9378